Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities
نویسندگان
چکیده
منابع مشابه
New possibilities in chemotherapy for colorectal cancer.
Colorectal cancer is the second leading cause of cancer death. Approximately 26,000 new cases are diagnosed yearly in France, resulting in more than 10,000 deaths, and 5-year survival remains low, at 40%. This poor prognosis is partly due to the fact that, in 30% of cases, colorectal cancer is metastatic or at a locally advanced stage when discovered. Moreover, visceral metastases complicate th...
متن کاملA review on miRNAs as new biomarkers for colorectal cancer
Background & Objective: Since colorectal cancer does not often have phenotypic symptoms in the early stages, the study of biomarkers for the diagnosis and prognosis of the tumor is very important. MicroRNAs are one of the most important biomarkers which attract the attention of many researchers due to a variety of reasons, including their non-invasive nature; these molecules are a group of non-...
متن کاملMetastatic Colorectal Cancer: Lessons Learned, Future Possibilities.
Survival of patients with metastatic colorectal cancer has dramatically improved over the past 20 years, primarily because physicians have become adept at using the many regimens approved for this patient population. Future advances may come from understanding molecular subtypes, finding and treating new actionable mutations, and harnessing the immune system.
متن کاملSafety profiles of current antiangiogenic therapies for metastatic colorectal cancer
The biological agents approved for the treatment of patients with metastatic colorectal cancer - bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A, along with cetuximab and panitumumab, two monoclonal antibodies that target the epidermal growth factor receptor - are associated with a number of adverse events that range in severity from relatively mild to poten...
متن کاملThe horizon of antiangiogenic therapy for colorectal cancer.
Vascular endothelial growth factor (VEGF) plays a crucial role in the growth and metastatic spread of cancer. Bevacizumab (Avastin) is the first commercially available VEGF inhibitor, earning U.S. Food and Drug Administration (FDA) approval in February 2004. In combination with fluorouracil (5-FU)-based chemotherapy, this agent significantly prolongs overall and progression-free survival of pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Colorectal Cancer
سال: 2013
ISSN: 1533-0028
DOI: 10.1016/j.clcc.2012.06.002